n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, November 29th, 2016

The QualityStocks
Daily Stock List

graphic
graphic

OptimizeRx Corp. (OPRX)

Marketbeat reported earlier this month on OptimizeRx Corp. (OPRX), Streetwise Reports and Bull in Advantage reported previously, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OptimizeRx Corp. provides innovative consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. The Company does so while providing pharmaceutical and healthcare companies effective ways to expand awareness, access, and adherence to their medications. The Company’s core product is SampleMD. OptimizeRx has its corporate headquarters in Rochester, Michigan.
 
The Company’s SampleMD replaces drug samples with electronic trial vouchers and co-pay coupon savings. These are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading Electronic Health Record (EHR) platforms in the country. These include Allscripts, Quest Diagnostics, Practice Fusion and greater than 350 other EHRs to reach over 250,000 healthcare providers.

OptimizeRx initially launched its SampleMD e-coupon solution in April of 2015 within Practice Fusion's EMR. The Company promotes patients’ savings and support from the world's largest pharmaceutical companies. These include Pfizer, Lilly, Novartis, AstraZeneca, and numerous others.

Additionally, OptimizeRx has launched OPTIMZEHR™. This is its consulting and implementation practice to assist pharmaceutical-biotechnology companies and healthcare provider platforms in determining and executing on mutually beneficial opportunities to jointly assist physicians and patients within their electronic health record (EHR) workflow.

OptimizeRx has acquired all the LogRx inventory for the remainder of 2016 and 2017 from Allscripts Healthcare, LLC (MDRX). With this expanded partnership, OptimizeRx will sell the Allscripts LogRx messaging solution. Allscripts Healthcare is an international leader in healthcare information technology solutions.

OptimizeRx has a new suite of services. These services integrate complete brand support into the EHR. This leads to enhanced patient care and improved outcomes. The new offerings include Brand Messaging and Brand Support.

The Company’s core product has been financial messaging, providing physicians with electronic coupons, co-pay offers, as well as vouchers for their patients at the point of care. OptimizeRx’s new brand support services include New Product Launch/ Drug File Integration; Sales Training and Support; and EHR Strategy and Planning.

OptimizeRx Corp. (OPRX), closed Tuesday's trading session at $0.88, down 9.28%, on 34,000 volume with 10 trades. The average volume for the last 60 days is 17,106 and the stock's 52-week low/high is $0.77/$1.32.

Enumeral Biomedical Holdings, Inc. (ENUM)

Marketbeat reported this month on Enumeral Biomedical Holdings, Inc. (ENUM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Enumeral Biomedical Holdings, Inc. is discovering and developing novel antibody immunotherapies that assist the immune system in attacking diseased cells. The Company is building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and taking advantage of the extensiveness of its technology via strategic collaborations. Its distinctive platform enables it to identify and characterize promising new drugs relevant to cancer, infectious, and inflammatory diseases. Enumeral Biomedical Holdings has its corporate headquarters in Cambridge, Massachusetts.

Enumeral is enabling and speeding up the discovery and development of novel antibody immunotherapies, or immunomodulators, which are validated with its human-driven immune profiling platform. The Company’s immunoprofiling platform harnesses The Power of Human™.

Enumeral believes that its cellular functional profiling techniques provide for a deeper understanding of the diversity of human responses and provide a more rational basis to guide immunotherapy design and development. It believes it has a unique ability to broadly interrogate the human immune microenvironment for candidate selection and validation.

The Company believes its inventive capabilities enable it to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, founded on a fundamental understanding of how immunotherapies work in each patient. The core technology underlying its platform was developed at, and licensed from, the Massachusetts Institute of Technology (MIT), Harvard University, and Whitehead Institute for Biomedical Research and Massachusetts General Hospital.

Enumeral is building a pipeline centered on next-generation checkpoint modulators, with initial targets including PD-1, TIM3, LAG-3, TIGIT, and VISTA. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform. This platform measures functioning of the human immune system at the level of individual cells. This provides important insights for candidate selection and validation.

Earlier, Enumeral announced that Mr. Wael Fayad was appointed Chairman, President, and Chief Executive Officer of the Company, effective September 21, 2016. Mr. Fayad brings to Enumeral Biomedical over 20 years of senior executive and business development experience in the life sciences industry. From 2001 to 2014, Mr. Fayad held positions of growing responsibility at Forest Laboratories, Inc., most recently as Corporate Vice President, Global Business Development.

Enumeral Biomedical is continuing to pursue its pipeline of antibody candidates. This includes its PD-1 antibody program. It selected one of its lead anti-PD-1 antibody candidates, called ENUM 244C8, for further development.

Enumeral Biomedical Holdings, Inc. (ENUM), closed Tuesday's trading session at $0.1699, up 19.65%, on 147,700 volume with 10 trades. The average volume for the last 60 days is 44,010 and the stock's 52-week low/high is $0.1082/$0.30.

CurAegis Technologies, Inc. (CRGS)

We are reporting on CurAegis Technologies, Inc. (CRGS) today, here at the QualityStocks Daily Newsletter.

CurAegis Technologies, Inc. develops and markets advanced technologies in the areas of power, safety, and wellness. The Company consists of two independent divisions - its CURA Division and its Aegis Division.  CurAegis is presently focusing on commercialization strategies in various technologies. These include the CURA system, which includes the myCadian™ watch that measures degradation of alertness and sleep attributes; the Z-Coach e-learning education and training tool, and the Aegis hydraulic pump. CurAegis Technologies is based in Rochester, New York.

The CURA System comprises hardware and software that measures multiple metrics to establish that a person's ability to perform a task or job appears to be degrading. The CURA division is developing a proprietary technology and family of products designed to measure the reduction in a person’s alertness and to train persons on how to improve alertness levels. The CURA™ system and the myCadian™ watch enable the user and third parties to anticipate and prevent undesired or disastrous situations caused by the degradation of alertness.

The Z-Coach e-learning tool was acquired by CurAegis Technologies in September 2015. The first of six Z-Coach e-learning modules, Z-Coach Aviation, has been designed for aviation professionals. Also, the Company’s Aegis hydraulic pump (Aegis Division) is an innovative hydraulic design. Its goal is to deliver better efficiencies in a package that is smaller and lighter than existing technologies.

This past August, Mr. Richard A. Kaplan, CurAegis Technologies’ Chief Executive Officer, announced that the Company entered into agreements with six companies to participate in the Beta Trials for the CurAegis’ proprietary CURA™ fatigue management system. The organizations represent five of CurAegis Technologies’ initial eight target markets. These include trucking, busing, aviation, medical, general corporate, sports science, and municipal agencies.

Regarding the CURA System, the Company completed its validation studies at the University of Colorado at Boulder and the University of Rochester Medical Center. CurAegis said that it can now state that it can predict a person’s fatigue level, at close to laboratory accuracy, in real-time. The Company said it will be releasing and distributing white papers and peer reviews over the next few months.

Pertaining to the Aegis Pump & Motor, CurAegis said that tests at the Milwaukee School of Engineering (MSOE) went well. It has set up meetings with prospective users. One of the largest potential customers asked CurAegis Technologies to produce a production prototype motor for them. They have given the Company their specifications. CurAegis is preparing to deliver it in July 2017.

CurAegis Technologies, Inc. (CRGS), closed Tuesday's trading session at $0.59, even for the day, on 4,337,265 volume with 114 trades. The average volume for the last 60 days is 2,808,011 and the stock's 52-week low/high is $0.0025/$0.031.

Echo Therapeutics, Inc. (ECTE)

StreetInsider, StockOodles, MarketWatch, TopPennyStockMovers, Wall Street Resources, SmarTrend Newsletters, and The Street reported earlier on Echo Therapeutics, Inc. (ECTE), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Echo Therapeutics, Inc. is a medical device company headquartered in Iselin, New Jersey. The Company’s concentration is on non-invasive continuous glucose monitoring (CGM) and associated technologies. It is developing its non-invasive, wireless, CGM system.

Echo Therapeutics became a public company on September 14, 2007 due to the merger of Sontra Medical Corp. and then privately held Echo Therapeutics, Inc. After this merger, Sontra Medical changed its name to Echo Therapeutics, Inc. on October 8, 2007. Echo’s shares trade on the OTCQB.

The Company has successfully demonstrated the ability to continuously monitor blood glucose non-invasively in healthy, Type I, Type II, and hospital patients. Individuals’ glucose data can be displayed on any mobile platform. The glucose data can also be accessed from the cloud for remote monitoring.

Echo Therapeutics says that a major opportunity exists for its CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. Furthermore, it says that a longer-term opportunity exists in hospital settings.

Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, including glucose, and enhanced delivery of topical pharmaceuticals. The Company’s precise exfoliator is an innovation in personal monitoring technology. The proprietary skin preparation device painlessly exfoliates an exact portion of the outer layer of dead skin. This is for optimal glucose and analyte extraction.

This past June, Echo Therapeutics announced that it commenced stand-alone and integrated testing of its NextGen continuous glucose monitoring system (CGM) prototype components. It also formally selected a Clinical Research Organization (CRO) for its regulatory and clinical strategy.

The Company began hardware and software testing of the NextGen Exfoliator and the Bluetooth transmitter. It continues to test the NextGen sensor element and hydrogel. Verification testing of the new Application Programming Interface (API) and software application (App) is finished.

In addition, in June, Echo Therapeutics received Institutional Review Board (IRB) approval for a new clinical protocol. The new protocol permits expanded testing of Echo's CGM system. Additionally, it allows the Company to recruit pediatric and adult subjects for its internal and external studies.

Echo Therapeutics, Inc. (ECTE), closed Tuesday's trading session at $0.344, up 0.58%, on 29,497 volume with 9 trades. The average volume for the last 60 days is 16,785 and the stock's 52-week low/high is $0.30/$2.8399.

Regen BioPharma, Inc. (RGBP)

ProTrader, SmallCapVoice, TopPennyStockMovers, Wall Street Mover, InvestorTrendz, and TheMicrocapNews reported on Regen BioPharma, Inc. (RGBP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Regen BioPharma, Inc. is a biotechnology company based in La Mesa, California. The Company works to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. Its aim is to rapidly advance these technologies by way of pre-clinical and Phase I/II clinical trials. Founded in 2012, Regen BioPharma is currently centering on checkpoint inhibitor and gene silencing therapies for treating cancer.

In addition, Regen BioPharma is focusing on developing stem cell treatments for aplastic anemia. The Company is now developing products treating blood disorders employing small molecules and gene silencing (DiffronC), and treating cancer with immunotherapy (dCellVax). Fundamentally, Regen BioPharma is working to increase the quality of life through therapies involving small molecules, stem cell treatments, and the body's own immune system.

Regen BioPharma is also modulating important molecular processes in cancer stem cells via its patented molecular targeting approaches (BORIS). It is also repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

Recently, Regen BioPharma announced that the Pan Am Cancer Treatment Center in Tijuana, Mexico presented final clinical data on their initial five patients. Starting in March 2016, five patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial one month follow up data were provided.

Pan Am Cancer Treatment Center has now provided three and six month follow up data in these same patients. The primary endpoint of the study is safety. The secondary endpoint is effectiveness.

Pan Am Cancer Treatment Center has been granted a non-exclusive license to test HemaXellerate in a first-in-human proof of concept study. Concerning safety, none of the five patients experienced any adverse events.  All the patients tolerated HemaXellerate with no side-effects.

Regen BioPharma also recently announced its strategy for developing its novel NR2F6 small molecule modulators. The Company recently filed a composition of matter patent application covering these novel NR2F6 small molecule modulators. It recently completed preliminary experiments demonstrating the immunological effects of these compounds. The next strategic steps are to further solidify the data, understand mechanisms of action and specificity, along with optimizing these compounds.

Regen BioPharma, Inc. (RGBP), closed Tuesday's trading session at $0.084, even for the day, on 5,691 volume with 5 trades. The average volume for the last 60 days is 166,446 and the stock's 52-week low/high is $0.0655/$0.219.

graphic

The QualityStocks
Company Corner

graphic
graphic

Net Element, Inc. (NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element, Inc. (NETE). Today, Net Element, Inc. closed trading at $0.9052, up 0.48%, on 86,031 volume with 198 trades. The stock’s average daily volume over the past 60 days is 132,242, and its 52-week low/high is $0.84/$4.60.

Net Element, Inc. today announced it has selected Conformance Technologies, a fast-growing provider of operating systems, education systems and expertise used in managing business compliance requirements as its preferred provider for data compliance solutions. Net Element will be offering PCI ToolKit in Chinese, English, Russian and Spanish languages for Payment Card Industry Data Security Standard (PCI DSS) merchant portfolio assessments. Net Element and its merchants will also have access to the Cyber Attack Readiness ToolKit™ and InConRadar™ toolsets for penetration testing, primary account number (PAN) scanning and real-time website monitoring of prohibited card brand acceptance activities.

Net Element, Inc. (NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprises in the United States and select emerging markets. Leveraging a network of subsidiaries operating in the mobile payments and value-added transactional services space – including Unified Payments, Aptito and PayOnline – Net Element is committed to promoting consistent and strong growth, as illustrated by its position as one of the South Florida Business Journal's 'Top 25 Fastest-Growing Technology Companies'. In the first seven months of 2016 alone, the company realized a 77 percent year-over-year increase in transactional processing volume when discounting the effects of foreign currency exchange.

A major contributor to this sustained growth has been Net Element's PayOnline subsidiary, which offers state-of-the-art payment technologies that are currently employed by more than 3,000 online enterprises across Europe and Asia. To bolster this position, the company has continued to expand its presence in Central Asia, most recently through the opening of a new office in Kazakhstan, the largest country in the region. Since its first anchor project in Kazakhstan in June 2015, PayOnline has entered agreements with more than 180 online merchants in Central Asia, and the region is expected to offer an opportunity for tremendous growth in the coming years as the proliferation of electronic commerce takes hold.

The growth of PayOnline throughout Eurasia has been accompanied by both awards and industry recognition. Independent analytical agency Markswebb Rank & Report ranked PayOnline as a top five payment acceptance company in its 2016 Internet Acquiring Rank report, and a second analytical agency, Tagline.ru, ranked PayOnline as a leading payment gateway in its 2016 Payment Systems Rating. The company's management team attributes this success to PayOnline's "innovative, customer-focused products and services."

Net Element is led by a seasoned management team offering a unique blend of leadership, vision, experience and creative energy. Oleg Firer, the company's chief executive officer, formerly served as the executive chairman of Unified Payments up until its acquisition by Net Element's TOT Group in April 2013. Under his guidance, Unified Payments achieved rapid growth, earning the top spot on Inc. Magazine's list of fastest-growing companies in 2012. As a result, Firer was recognized by Forbes as one of the 'Five Incredible Entrepreneurs' and by Business Leader Magazine as a 'Top Entrepreneur in South Florida'. Disclaimer

Net Element, Inc. Company Blog

Net Element, Inc. News:

Net Element Partners with Conformance Technologies

Net Element Partners with Mashreqbank in United Arab Emirates

Net Element Reports Third Quarter and Nine Months Ended September 30, 2016 Results Recent Highlights

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0014, up 7.69%, on 5,752,161 volume with 25 trades. The stock’s average daily volume over the past 60 days is 18,521,151 and its 52-week low/high is $0.001/$0.06.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Secures Gas Supply for South Africa

Dominovas Energy Dispatches Watkins to Meet With Gas Supplier

Dominovas Energy Presents the Findings of Energy Survey to University of Johannesburg

Agora Holdings, Inc. (AGHI)

The QualityStocks Daily Newsletter would like to spotlight Agora Holdings, Inc. (AGHI). Today, Agora Holdings, Inc. closed trading at $0.10474, up 0.13%, on 24,383 volume with 11 trades. The stock’s average daily volume over the past 60 days is 571,924, and its 52-week low/high is $0.01/$0.49.

Agora Holdings, Inc. (AGHI), together with its wholly-owned subsidiary, Geegle Media, is leading a diversified family entertainment and media enterprise through business segments which include: TV on Demand, interactive media, business products and consumer platforms. With its multi-dimensional approach, Geegle Media supports Agora Holdings' mission to deliver innovate and high-quality business solution products and to deliver video content from around the world.

Geegle Media web platforms include; GeegleTV, Frame, 1000Salads, RealtyTV and LobbyTV. Geegle TV is a multi-platform video entertainment website that curates high-quality video content from around the world. In 2016, GeegleTV will serve as co-producer by airing original content. By exposing undiscovered content to millions of users and rendering it shareable to social media, Geegle TV will serve as a marketing partner to local and internationally based TV shows not yet on the open market.

For commercial use, Geegle Media provides a variety of solutions that include web development and billing software for VoIP applications. RealtyTV is its state-of-the-art platform for real estate brokerages. LobbyTV is another of its widely used products by business offices. For individuals, Geegle TV combines radio, On Demand movies, news, sports and children's content.

Geegle Media is also developing 1000salads, an online hub that encourages healthy lifestyles. The portal will feature recipes and products, health-oriented articles and a curated selection of local restaurants and grocers that deliver to the health-conscious user. Currently in its alpha stage of development, 1000salads is gearing up its sales and marketing in preparation for its launch in 2016.

Geegle Media differs from other On Demand providers, such as Netflix and HBO, in that its service is free of constraints such as subscription, fees and penalties. As consumers increasingly opt for personalized sources of entertainment, Agora recognizes the vast opportunities and growth potential provided by the rising popularity of TV On Demand. The company also benefits from strong and visionary management with a track record of bringing innovative ideas to fruition. Disclaimer

Agora Holdings, Inc. Company Blog

Agora Holdings, Inc. News:

Agora Holdings, Inc. Updates FRAME Technology to Expand Business-Use Capabilities

Agora Holdings, Inc. Issues Corporate Update on Current, Future Endeavors

Agora Holdings, Inc. Launches FRAME Social Media App

GainClients, Inc. (GCLT)

The QualityStocks Daily Newsletter would like to spotlight GainClients, Inc. (GCLT). Today, GainClients, Inc. closed trading at $0.0396, off by 26.01%, on 337,915 volume with 31 trades. The stock’s average daily volume over the past 60 days is 184,101, and its 52-week low/high is $0.01/$0.20.

GainClients, Inc. (GCLT) is a software service company focused primarily on the development of marketing services for real estate professionals and valuable home search and area information tools for consumers. The company's innovations expound the popularity of online networks by helping real estate professionals better serve their clients through the sharing of accurate real estate data.

The company's main product is the GCard progressive networking system, which is designed to build and promote relationships among real estate professionals and their clients. Using the GCard, agents and brokers have the means to offer real estate, lending and title services information through an integrated, web-based network, capitalizing on the ongoing shift in consumer preference toward mobile solutions.

Similar to the features of other popular online networks, professional users can invite clients and their industry partners to join their GCard networks and be featured as trusted team members. From here, the teams can quickly provide real estate, lending and title services and information to consumers via smartphone and web. With better communication throughout the process of buying or selling homes, purchases can move more quickly and more comfortably to completion.

Strategic partnerships are an important component of GainClients' growth strategy. The company recently established a worldwide licensing arrangement with CLOVIS LLC, a partnership that will enable the distribution of both companies' proprietary technologies to the real estate industry. CLOVIS will use GainClients' GCard to develop a unique lead generation program for the broader real estate marketing and advertising industry.

GainClients also offers GCHomeSearch, its stand-alone website that provides non-real estate customers, such as lenders and title professionals, with accurate listing data, historical property data, neighborhood information and demographics. When used with the GCard, the user is also privy to loan payment calculators, loan rates, closing cost estimators and other tools needed to make intelligent buying and selling choices. Disclaimer

GainClients, Inc. Company Blog

GainClients, Inc. News:

GainClients, Inc. Retains Largest Real Estate Customer on its GCard Service

GainClients, Inc. Announces Corporate Update

GainClients, Inc. Enters Into A Licensing Agreement with Real Estate Technology Upstart CLOVIS, LLC To Expand Its Technology Platform

iGambit, Inc. (IGMB)

The QualityStocks Daily Newsletter would like to spotlight iGambit, Inc. (IGMB). Today, iGambit, Inc. closed trading at $0.07, even for the day. The stock’s average daily volume over the past 60 days is 29,400, and its 52-week low/high is $0.015/$0.16.

iGambit, Inc. (IGMB) is a diversified holding company focused primarily on the acquisition of early-stage technology firms with strong growth potential that's easily recognized in the public arena. Leveraging the considerable industry experience of its board of directors and management team, iGambit offers talented entrepreneurs an opportunity to focus their time and energy on building a business instead of searching out investors or raising capital. Following acquisition, iGambit provides the capital and management expertise required to help its partner firms flourish with the intention of 'spinning off' the acquisition to the benefit of both the newly independent business and iGambit shareholders.

One of iGambit's most recent acquisitions occurred in November 2015, when the company added ArcMail to its portfolio. Founded to help clients boost email server performance and satisfy associated regulatory requirements, ArcMail is a leading provider of simple, secure and cost-effective email and enterprise archiving and management solutions. In April 2016, the marketability of ArcMail's technology was highlighted when the firm was selected as a 'Top 20 Enterprise Security Company of 2016' by leading IT publication CIOReview.

At the core of iGambit's business model is its experienced leadership team. John Salerno, chairman of iGambit, is a seasoned executive with more than four decades of experience in the technology industry. In addition to providing consulting services to a wide range of clients, Salerno founded a startup that later became a multi-million dollar business servicing the New York real estate market. In 1996, he cofounded bigVAULT, Inc., an online backup and file-sharing company that later became iGambit following an asset purchase sale with Verizon and Cablevision.

In June 2016, iGambit appointed Rory Welch as its chief executive officer. Welch originally joined the iGambit team through the ArcMail acquisition, bringing more than 20 years of senior management experience spanning multiple industries and global geographies to the company. Prior to serving as ArcMail's president and CEO, Welch managed his own consulting firm, which attracted clients ranging from Fortune 100 companies to mid-market players across a number of industry verticals. Welch also held leadership positions at Movado Group, Inc., as well as Arrow Electronics, where he was responsible for overseeing all aspects of product management for the tech firm's $1 billion Asia-Pacific division. Disclaimer

iGambit, Inc. Company Blog

iGambit, Inc. News:

HubCentrix Inc. and iGambit Inc. Sign Letter of Intent for iGambit Inc. to Acquire the Assets of HubCentrix Inc.

EncounterCare and iGambit Inc. Sign Letter of Intent for iGambit Inc. to Acquire Certain Assets of CyberCare Health Network Inc.

iGambit Names Rory Welch as CEO; John Salerno Remains Chairman

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

DSR News
(INCT)

2.

Wall Street Mover
(BEST)

3.

Penny Stock Titans
(AEXE)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251